TTX 334E
Alternative Names: TTX-334; TTX-334ELatest Information Update: 24 Feb 2023
At a glance
- Originator Temple Therapeutics
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Peroxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Ovarian cancer
Highest Development Phases
- Preclinical Endometriosis
- No development reported Ovarian cancer
Most Recent Events
- 02 Feb 2023 Preclinical trials in Endometriosis in Netherlands (Parenteral) (Temple Therapeutics pipeline; January 2023)
- 28 Jun 2022 No recent reports of development identified for preclinical development in Ovarian-cancer in Netherlands
- 06 Jun 2018 Temple therapeutics has patents pending for "Antibodies to treat solid tumors" in the US